PHARMACOKINETICS OF MIDAZOLAM IN RELATION TO POLYMORPHIC SPARTEINE OXIDATION

被引：17

作者：

KLOTZ, U

MIKUS, G

ZEKORN, C

EICHELBAUM, M

机构：

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 1986年 / 22卷 / 05期

关键词：

D O I：

10.1111/j.1365-2125.1986.tb02946.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：618 / 620

页数：3

共 11 条

[1] MIDAZOLAM KINETICS [J].

ALLONEN, H ;

ZIEGLER, G ;

KLOTZ, U .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (05) :653-661

[2] PROLONGED MIDAZOLAM ELIMINATION HALF-LIFE [J].

DUNDEE, JW ;

COLLIER, PS ;

CARLISLE, RJT ;

HARPER, KW .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 21 (04) :425-429

[3] DEFECTIVE N-OXIDATION OF SPARTEINE IN MAN - NEW PHARMACOGENETIC DEFECT [J].

EICHELBAUM, M ;

SPANNBRUCKER, N ;

STEINCKE, B ;

DENGLER, HJ .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (03) :183-187

[4] POLYMORPHIC OXIDATION OF SPARTEINE AND DEBRISOQUINE - RELATED PHARMACOGENETIC ENTITIES [J].

EICHELBAUM, M ;

BERTILSSON, L ;

SAWE, J ;

ZEKORN, C .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 31 (02) :184-186

[5]

EICHELBAUM M, 1982, CLIN PHARMACOKINET, V7, P1, DOI 10.2165/00003088-198207010-00001

[6] A FAMILY AND POPULATION STUDY OF THE GENETIC-POLYMORPHISM OF DEBRISOQUINE OXIDATION IN A WHITE BRITISH-POPULATION [J].

EVANS, DAP ;

MAHGOUB, A ;

SLOAN, TP ;

IDLE, JR ;

SMITH, RL .

JOURNAL OF MEDICAL GENETICS, 1980, 17 (02) :102-105

[7]

HEIZMANN P, 1981, ARZNEIMITTEL-FORSCH, V31-2, P2220

[8]

INABA T, 1985, DRUG METAB DISPOS, V13, P443

[9]

KANTO JH, 1985, PHARMACOTHERAPY, V5, P138

[10] PHYSIOLOGIC AND TEMPORAL VARIATION IN HEPATIC ELIMINATION OF MIDAZOLAM [J].

KLOTZ, U ;

ZIEGLER, G .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 32 (01) :107-112

← 1 2 →